CN107533062B - 用于胰腺癌的生物标志物 - Google Patents

用于胰腺癌的生物标志物 Download PDF

Info

Publication number
CN107533062B
CN107533062B CN201680018784.8A CN201680018784A CN107533062B CN 107533062 B CN107533062 B CN 107533062B CN 201680018784 A CN201680018784 A CN 201680018784A CN 107533062 B CN107533062 B CN 107533062B
Authority
CN
China
Prior art keywords
protein
pdac
urine
sample
biomarker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680018784.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN107533062A (zh
Inventor
T·茨诺戈拉-朱斯维克
T·拉多纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queen Mary University of London
Original Assignee
Queen Mary University of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queen Mary University of London filed Critical Queen Mary University of London
Publication of CN107533062A publication Critical patent/CN107533062A/zh
Application granted granted Critical
Publication of CN107533062B publication Critical patent/CN107533062B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Primary Health Care (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201680018784.8A 2015-02-05 2016-02-05 用于胰腺癌的生物标志物 Active CN107533062B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1501930.0 2015-02-05
GBGB1501930.0A GB201501930D0 (en) 2015-02-05 2015-02-05 Biomarkers for pancreatic cancer
PCT/GB2016/050277 WO2016124947A1 (en) 2015-02-05 2016-02-05 Biomarkers for pancreatic cancer

Publications (2)

Publication Number Publication Date
CN107533062A CN107533062A (zh) 2018-01-02
CN107533062B true CN107533062B (zh) 2021-03-23

Family

ID=52746188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680018784.8A Active CN107533062B (zh) 2015-02-05 2016-02-05 用于胰腺癌的生物标志物

Country Status (15)

Country Link
US (3) US10782301B2 (https=)
EP (2) EP4458849A3 (https=)
JP (1) JP6786499B2 (https=)
KR (1) KR102569984B1 (https=)
CN (1) CN107533062B (https=)
AU (1) AU2016214140B2 (https=)
BR (1) BR112017016808A2 (https=)
CA (1) CA2974775C (https=)
CL (1) CL2017001972A1 (https=)
GB (1) GB201501930D0 (https=)
HK (1) HK1247276A1 (https=)
IL (1) IL253710B (https=)
MX (1) MX2017009998A (https=)
SG (1) SG11201706223VA (https=)
WO (1) WO2016124947A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2681899C (en) 2007-03-27 2018-06-19 Immunovia Ab Methods for diagnosis of pancreatic adenocarcinoma, and biomarkers and arrays for use in the same
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) * 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer
CN107674884A (zh) * 2017-09-05 2018-02-09 上海速创诊断产品有限公司 一种用于检测胰腺癌标记物reg1a的生物素化脂质体及其制备方法和应用
TWI643869B (zh) * 2017-12-14 2018-12-11 國立高雄大學 Molecular extension printing material and preparation method thereof, magnetic molecular extension printing material and preparation method thereof
US20210052231A1 (en) * 2017-12-14 2021-02-25 Salcit Technologies Private Limited Method and system for analyzing risk associated with respiratory sounds
KR102000387B1 (ko) * 2018-02-13 2019-07-15 서울대학교산학협력단 췌관내유두상점액종양의 악성도를 감별할 수 있는 단백질 바이오마커 및 그 용도
CN109358055A (zh) * 2018-12-18 2019-02-19 沈阳理工大学 增敏测定空气中氨的混合指示剂试纸及其制备和检测方法
CN111303281A (zh) * 2019-05-14 2020-06-19 长春恒晓生物科技有限责任公司 制备胰石蛋白抗体及建立检测psp方法
EP4045912A1 (en) * 2019-10-18 2022-08-24 Reccan Diagnostics AB Apparatuses and methods for detection of pancreatic cancer
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
US20240255524A1 (en) * 2021-06-15 2024-08-01 Somalogic Operating Co., Inc. Renal Insufficiency Prediction and Uses Thereof
CN113248609B (zh) * 2021-07-14 2021-09-10 深圳市盛波尔生命科学技术有限责任公司 针对再生胰岛衍生蛋白1α的抗体组合以及包含其的检测试剂盒
CN115290732B (zh) * 2022-07-14 2025-02-25 西北大学 一种检测胰蛋白酶的电化学生物传感器及其制备方法
CN119724622B (zh) * 2024-11-25 2025-12-12 中国人民解放军总医院第五医学中心 一种评价ptt对胰腺癌治疗效果的方法、系统及设备

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140304A1 (en) * 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2009147530A2 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals Ltd Conformation specific antibodies that bind trefoil factors
CN101743476A (zh) * 2006-10-03 2010-06-16 尼瑞医药品有限公司 结合三叶因子的构象特异性抗体以及使用该抗体治疗癌症以及增殖疾病的方法
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
WO2013043644A1 (en) * 2011-09-21 2013-03-28 The University Of North Carolina At Chapel Hill Methods using liver disease biomarkers
WO2013106844A2 (en) * 2012-01-13 2013-07-18 Oncocyte Corporation Methods and compositions for the treatment and diaginosis of pancreatic cancer
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444879A (en) * 1981-01-29 1984-04-24 Science Research Center, Inc. Immunoassay with article having support film and immunological counterpart of analyte
GB9827228D0 (en) 1998-12-10 1999-02-03 Univ Nottingham Cancer detection method and reagents
ES2320443T3 (es) * 2002-09-30 2009-05-22 Oncotherapy Science, Inc. Genes y polipeptidos relacionados con canceres pancreaticos humanos.
AU2003900747A0 (en) 2003-02-18 2003-03-06 Garvan Institute Of Medical Research Diagnosis and treatment of pancreatic cancer
US20050095611A1 (en) 2003-05-02 2005-05-05 Chan Daniel W. Identification of biomarkers for detecting pancreatic cancer
WO2004102189A1 (en) 2003-05-15 2004-11-25 Europroteome Ag Biomarkers for the differential diagnosis of pancreatitis and pancreatic cancer
DE102004042822A1 (de) 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE602006018578D1 (de) 2005-01-28 2011-01-13 Childrens Medical Center Diagnose- und prognoseverfahren von blasenkrebs.
US20070031867A1 (en) 2005-06-27 2007-02-08 John Wayne Cancer Institute Molecular/genetic aberrations in surgical margins of resected pancreatic cancer represents neoplastic disease that correlates with disease outcome
WO2007035684A2 (en) 2005-09-16 2007-03-29 Primera Biosystems, Inc. Method for quantitative detection of short rna molecules
JP5490413B2 (ja) 2006-01-05 2014-05-14 ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常
WO2007098102A2 (en) 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
US20070231822A1 (en) 2006-02-28 2007-10-04 Michael Mitas Methods for the detection and treatment of cancer
WO2008036765A2 (en) 2006-09-19 2008-03-27 Asuragen, Inc. Micrornas differentially expressed in pancreatic diseases and uses thereof
WO2008063479A2 (en) * 2006-11-17 2008-05-29 Fred Hutchinson Cancer Research Center Pancreatic cancer biomarkers
CA2685840C (en) 2007-04-30 2016-12-13 The Ohio State University Research Foundation Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis
JP2012100536A (ja) * 2009-03-02 2012-05-31 Genescience Co Ltd 血液試料に含まれる単核球細胞を用いた癌関連遺伝子の発現解析による癌の遺伝子検査方法
WO2011090492A1 (en) * 2010-01-19 2011-07-28 Immunomedics, Inc. Novel class of monospecific and bispecific humanized antibodies that target the insulin-like growth factor type i receptor (igf-1r)
EP2415877A3 (en) * 2010-02-17 2012-02-15 Deutsches Krebsforschungszentrum Means and methods for diagnosing pancreatic cancer
WO2011137288A2 (en) 2010-04-30 2011-11-03 The Ohio State University Mirna networks in cancers and leukemias and uses thereof
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
DE102012204366B4 (de) 2011-12-16 2017-07-27 Siemens Aktiengesellschaft Verfahren und Kit zur Identifizierung und Quantifizierung von einer einzelsträngigen Ziel-Nukleinsäure
EP2804958A2 (en) 2012-01-16 2014-11-26 Herlev Hospital Microrna for diagnosis of pancreatic cancer and/or prognosis of patients with pancreatic cancer by blood samples
US20130216545A1 (en) * 2012-02-19 2013-08-22 Claresa Levetan Early Diagnosis and Novel Treatment of Cancer
US20130317083A1 (en) 2012-05-04 2013-11-28 Thomas Jefferson University Non-coding transcripts for determination of cellular states
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
US20150018230A1 (en) 2013-06-11 2015-01-15 Indiana University Research And Technology Corp. PLASMA miRNA SIGNATURE FOR THE ACCURATE DIAGNOSIS OF PANCREATIC DUCTAL ADENOCARCINOMA
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
GB201517028D0 (en) 2015-09-25 2015-11-11 Univ London Queen Mary Novel biomarkers for pancreatic cancer

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101743476A (zh) * 2006-10-03 2010-06-16 尼瑞医药品有限公司 结合三叶因子的构象特异性抗体以及使用该抗体治疗癌症以及增殖疾病的方法
WO2009140304A1 (en) * 2008-05-12 2009-11-19 Genomic Health Inc. Tests to predict responsiveness of cancer patients to chemotherapy treatment options
WO2009147530A2 (en) * 2008-06-06 2009-12-10 Neuren Pharmaceuticals Ltd Conformation specific antibodies that bind trefoil factors
WO2012100339A1 (en) * 2011-01-27 2012-08-02 University Health Network Methods and compositions for the detection of pancreatic cancer
WO2013043644A1 (en) * 2011-09-21 2013-03-28 The University Of North Carolina At Chapel Hill Methods using liver disease biomarkers
WO2013106844A2 (en) * 2012-01-13 2013-07-18 Oncocyte Corporation Methods and compositions for the treatment and diaginosis of pancreatic cancer
WO2013152989A2 (en) * 2012-04-10 2013-10-17 Eth Zurich Biomarker assay and uses thereof for diagnosis, therapy selection, and prognosis of cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis.;Mindy Porterfield, et al.;《J Proteome Res》;20140207;第13卷(第2期);第1-28页 *
Mindy Porterfield, et al..Discrimination between adenocarcinoma and normal pancreatic ductal fluid by proteomic and glycomic analysis..《J Proteome Res》.2014,第13卷(第2期), *
Thiruvengadam Arumugam, et al..Trefoil Factor 1 Stimulates Both Pancreatic Cancer and Stellate Cells and Increases Metastasis..《Pancreas》.2011,第40卷(第6期), *
Trefoil Factor 1 Stimulates Both Pancreatic Cancer and Stellate Cells and Increases Metastasis.;Thiruvengadam Arumugam, et al.;《Pancreas》;20110831;第40卷(第6期);摘要，第3-5页 *
Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer.;ZOFIA VON MARSCHALL, et al.;《International Journal of Oncology》;20050930;第27卷(第3期);第669-679页 *
ZOFIA VON MARSCHALL, et al..Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer..《International Journal of Oncology》.2005,第27卷(第3期),第669-679页. *
人胰腺癌组织LYVE-1表达与癌组织淋巴管转移关系研究;何军，等;《齐齐哈尔医学院学报》;20081231;第29卷(第15期);第1797-1799页 *
何军，等.人胰腺癌组织LYVE-1表达与癌组织淋巴管转移关系研究.《齐齐哈尔医学院学报》.2008,第29卷(第15期), *

Also Published As

Publication number Publication date
JP6786499B2 (ja) 2020-11-18
EP3254111A1 (en) 2017-12-13
MX2017009998A (es) 2018-02-01
KR20170129118A (ko) 2017-11-24
WO2016124947A1 (en) 2016-08-11
BR112017016808A2 (pt) 2018-04-03
EP4458849A2 (en) 2024-11-06
JP2018504609A (ja) 2018-02-15
CA2974775A1 (en) 2016-08-11
KR102569984B1 (ko) 2023-08-22
US10782301B2 (en) 2020-09-22
US20220042998A1 (en) 2022-02-10
US11977077B2 (en) 2024-05-07
US20190204323A1 (en) 2019-07-04
HK1247276A1 (zh) 2018-09-21
CN107533062A (zh) 2018-01-02
CA2974775C (en) 2023-11-07
IL253710B (en) 2020-08-31
AU2016214140A1 (en) 2017-08-17
AU2016214140B2 (en) 2021-11-04
CL2017001972A1 (es) 2018-03-23
GB201501930D0 (en) 2015-03-25
SG11201706223VA (en) 2017-08-30
US20250251399A1 (en) 2025-08-07
EP4458849A3 (en) 2024-12-04
IL253710A0 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CN107533062B (zh) 用于胰腺癌的生物标志物
Belczacka et al. Proteomics biomarkers for solid tumors: Current status and future prospects
WO2021076036A1 (en) Apparatuses and methods for detection of pancreatic cancer
JP2016538545A (ja) 肝臓癌の診断及び予後判定のための材料及び方法
CN111065925B (zh) Agrin在诊断子宫内膜癌中的应用
WO2015149030A1 (en) Protein biomarker profiles for detecting colorectal tumors
KR102087373B1 (ko) 비소세포성 폐암 진단용 단백질 바이오마커 패널 및 이를 이용한 비소세포성 폐암 진단 방법
JP2018518683A (ja) バイオマーカーパネルに基づいて対象における膵癌を診断するための手段および方法
CN104204807A (zh) 用于胃癌的生物标志物及其应用
US10338076B2 (en) Methods and compositions for the diagnosis of ovarian cancer
US20180224456A1 (en) Method for determining a subject's probability to suffer from pancreatic cancer
Sa et al. Proteomic approaches to assist in diagnosis and prognosis of oral cancer
US20180274037A1 (en) Novel biomarkers for pancreatic diseases
US20240044902A1 (en) Methods for the detection and treatment of ovarian cancer
WO2019115679A1 (en) A signature to assess prognosis and therapeutic regimen in liver cancer
CN117355748A (zh) 结直肠癌的生物标志物
HK40118234A (en) Biomarkers for pancreatic cancer
HK40105704A (zh) 肺癌的检测和治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant